Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

The CHAI platform extracted quantitative histomorphologic features from whole-slide images of hematoxylin and eosin–stained diagnostic biopsies. In a multi-institutional development cohort, features ...

Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other related disorders, represent a ...

Please provide your email address to receive an email when new articles are posted on . ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for ...

The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 21-22, 2010, bringing together key stakeholders, to present promising current and emerging technologies with ...

We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...

Tuberculosis (TB) remains one of the world's most serious public health threats, with approximately one-quarter of the global ...

Aging is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a ...